A daily, 5-10 minute, podcast where we talk about risk and investing. Find out more at mattcorc.com or shoot me an email at matt@mattcorc.com. I would love to hear any feedback, including topic suggestions and insurance questions. If you would like to join me on an episode, send me an email.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Where does the market go from here? Will retail investors sell?
9:21
9:21
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
9:21
We talk about the recent market turmoil and how that will impact investor actions. Will investors stick to their guns or succumb and sell if the market continues to sell off. A few comments on Medtronic’s settlement and how insurance could have been implemented to reduce the financial burden for Medtronic.…
…
continue reading
GE has seen its market cap decrease by over $200B since 2016 and it now trades at around $8. Is this the correct value or should it be higher or perhaps lower?
…
continue reading
![Artwork](/static/images/128pixel.png)
1
We changed our name and Amazon announced their new locations!
10:31
10:31
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
10:31
Why we changed our name to the MattCorc Podcast. Who is taking the most risk with the Amazon headquarters, Amazon or the local/state government? What is Waymo? The first autonomous ride hailing service is getting ready to launch in Arizona.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
A $500 Million Biotech IPO. Amarin Data
9:04
9:04
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
9:04
Moderna plans the biggest biotech IPO ever and we learn more about Amarin’s clinical study. Was mineral oil the best choice of placebo? Lessons we can learn from Amarin about D&O insurance.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Herd Mentality. Why D&O benchmarking is a sales ploy. What to use to make a more informed decision.
9:14
9:14
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
9:14
I talk about how brokers use benchmarking to sell you more D&O insurance. Brokers take advantage of herd mentality so insurers buy more D&O than they need.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Why cost should only be one consideration
5:24
5:24
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
5:24
Cost and its importance are discussed. Minor differences in coverage can cause major headaches when you have a claim.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S&P Companies not as negative; Gene Therapy manufacturing is stretched thin
7:21
7:21
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
7:21
Happy national doughnut day! Fewer companies in the S&P are providing negative guidance. What does this mean? How CFOs are protecting their balance sheets in the event their manufacturing is disrupted.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Lessons from Halloween when your kids have peanut allergies
8:56
8:56
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
8:56
Why is Aimmune (AIMT) up today? Is it because Halloween reminded investors how many types of candy have peanuts in them? A lesson on how to make sure you aren’t missing significant coverage gaps in your insurance program. Hint: I learned it from checking my kids Halloween candy.
…
continue reading
How my first time swimming in a lap pool in years was a good metaphor for today’s market and some other interesting facts on the financial markets.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
President’s Drug Pricing Speech and New CA Sexual Harassment Law
8:49
8:49
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
8:49
An overview of the President’s drug pricing proposal and what the new California sexual harassment law could mean for your insurance.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
M&A Activity - Will Market Forces Play a Role?
3:28
3:28
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
3:28
With biotech stocks sinking, the XBI just hit a 52 week low, and interest rates rising will we see an urgency for acquisitions to be done?
…
continue reading
Quick post on why Insurance buying doesn’t need to be so abstract.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 35 - McDermott Will & Emery Dealmaking Symposium Recap
9:57
9:57
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
9:57
A ton was learned at the MWE life science deal making symposium and here I share that with you.
…
continue reading
A synopsis of DeviceTalks Boston. Pathways to acquisition, hurdles that you might face and how to derisk your company to make it more appealing to investors and acquiring companies.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 33 - Chinese Espionage and Cyber Coverage
6:17
6:17
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
6:17
What can we learn from the alleged Chinese cyber espionage incident and how cyber insurance could respond.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 32 - Can the Biotech IPO Market Sustain Itself?
5:35
5:35
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
5:35
I would love to hear whether people believe the pace of biotech IPOs will continue. Hear my thoughts and share yours at mattcorc.com.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
I’m Doing an IPO and My D&O Insurance is Expensive
8:03
8:03
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
8:03
Why D&O Insurance is expensive for life science companies and how the stage your company is in impacts pricing.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
FDA Condemns Undamaged Product - Insurance Should Have Paid
5:16
5:16
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
5:16
A client had a fire and $250,000 in product was destroyed. Undamaged condemned stock was valued at over $500,000 but there insurance did not cover it. Find out why that should never happen.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 29 - MD Bio-Tech Conference Recap
11:28
11:28
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
11:28
A recap of the Maryland Bio-Tech Conference that I recently attended.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 28 - NJTC CFO Forum Recap
10:20
10:20
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
10:20
A recap of the CFO Forum put on by the NJ Tech Council. The speaker was Jim Mastakas who was the CFO of Amneal when they merged with Impax Labs
…
continue reading
The impacts of Hurricane Florence on the property insurance market are discussed
…
continue reading
Why does a pre-clinical company need insurance?
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Apple Watch, Transitioning From Digital Health to Med Device
5:36
5:36
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
5:36
A quick synopsis of how insurance liability changes as a company enters the realm to an FDA regulated product.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Hurricane Florence and Where to Look for Property Coverage
9:19
9:19
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
9:19
Where to look for additional coverage in your proprty policy above and beyond replacing your building or contents. Things to be aware of that could reduce coverage.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Abbvie Testosterone Settlement and Product Liability
10:26
10:26
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
10:26
I discuss the Abbvie testosterone settlement and the role of product liability insurance could play. Hurricanes and property insurance.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 22 - Boston Biotech Week and RESI
8:47
8:47
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
8:47
A recap of Boston Biotech Week and the RESI conference. How insurance can help you stand out with investors.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 21 - Patent Insurance...It’s a Real Thing
9:29
9:29
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
9:29
An overview of patent insurance and what it can do.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 20 - Opioid Settlement and Product Liability
10:27
10:27
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
10:27
A discussion on Product Liability insurance in relation to a possible opioid settlement. Wage & Hour lawsuits are on the rise but there is a solution.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
What happens when your supply chain is disrupted?
7:17
7:17
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
7:17
In the wake of an API manufacturer being shut down in China I discuss using insurance to mitigate the cash flow disruption.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Should Public Companies Only Report Earnings Semi-Annually?
7:55
7:55
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
7:55
The possible impacts on moving from quarterly to semiannual reporting periods for public companies on the D&O insurance marketplace
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 17 - Getting Your Product Approved
10:28
10:28
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
10:28
Amicus and Alnylam both got FDA approval last week. Find out how that can change their risk profile.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Cyber Insurance - Is Change Coming?
7:49
7:49
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
7:49
I discuss the PGA Championship being cyber extorted, CA Consumer Privacy Act and the role insurance plays in both of these events.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Apple, AIG, D&O Insurance and Patents
10:53
10:53
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
10:53
We discuss Apple hitting the $1 trillion mark, AIG going the other way, government taking your patent and D&O insurance
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 14 - Securities Class Action Filings and D&O Cover
8:09
8:09
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
8:09
I talk about the prevalence of securities class action filings and how D&O can protect you. I also discuss how we should not choose limits solely by what our peers have in place.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 13 - Sarepta and Insuring Regulatory Risk
4:18
4:18
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
4:18
I talk about what we can learn from Sarepta's clinical hold and how they could insure such an event for their commercial product.
…
continue reading
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Keryx Merger and Supply Chain issues
6:07
6:07
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
6:07
Today we are reminded, due to the news that Keryx and Akebia are merging, of what happens when you have a supply chain issue.
…
continue reading
Aquinox disaster and what you can do to protect your company from Black Swans.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Stryker Acquisition, CRISPR problems
4:41
4:41
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
4:41
Recap of today’s big events. Stryker bidding on Boston Scientific. CRISPR might cause cancer.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Liability for Digital Health Products
7:56
7:56
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
7:56
I discuss liability when a digital health product works but something bad happens. Blurring the lines of medtech and digital health.
…
continue reading
A brief review of the 2018 Medtech conference in Minneapolis
…
continue reading
IPO market is healthy. Rockwell Medical and how D&O insurance could provide balance sheet protection
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 5 - Keytruda, Rockwell Medical, Spoilage
6:29
6:29
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
6:29
Keytruda does it again in the clinic and also changes to M&A landscape. What’s going on at Rockwell Medical? Is your product temperature sensitive?
…
continue reading
Quick rundown on FDA related news, Hemophilia news and how right to try could impact the insurance market
…
continue reading
…
continue reading
…
continue reading
Episode 1 - Drug Pricing and Ford
…
continue reading